# GLP-1 Antagonist Shows Clinically Meaningful Results in Post-Bariatric Hypoglycemia

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/obesityweek/123896) · 2026-11-16 · Medicine
Page: https://themorning.science/story/glp-1-antagonist-shows-clinically-meaningful-results-in-post-bariatric-hypoglyce-f8232b2d0f3035fe
Kind: research · Impact: medium

## In brief

- An investigational first-in-class GLP-1 receptor antagonist significantly reduced hypoglycaemic events after bariatric surgery in the phase III LUCIDITY trial.
- The reported baseline mean was 2.39 hypoglycaemic events per period; the source text is cut off before the period and the post-treatment figures are not given.
- The results were presented at ObesityWeek in National Harbor, Md., and described by MedPage Today as clinically meaningful.

## Why it matters

Post-bariatric hypoglycaemia is a recurring complication with few targeted treatments, so a phase III result with a significant reduction in events is relevant to clinicians and researchers in obesity and metabolic medicine. The drug is still investigational and not approved.

## Coverage

- [GLP-1 Antagonist Shows Clinically Meaningful Results in Post-Bariatric Hypoglycemia](https://www.medpagetoday.com/meetingcoverage/obesityweek/123896) — MedPageToday.com - medical news for physicians, 2026-11-16

Tags: glp-1, bariatric surgery, hypoglycaemia, clinical trial, obesity

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
